 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 April 1995 | Volume 122 Issue 7 | Pages 511-513
Objective: To determine the serum level of free 1,25-dihydroxyvitamin D (1,25-[OH]2D) in patients with vitamin D toxicity and to assess the in vitro effect of differing concentrations of vitamin D metabolites on the free serum levels of 1,25-(OH)2D.
Design: 1] A case study of patients hospitalized with vitamin D toxicity after accidentally ingesting a veterinary vitamin D concentrate and 2) an in vitro experiment in which vitamin D metabolites in various concentrations were added to normal serum and their effect was noted on percentage of free 1,25-(OH)2D.
Patients: 11 patients (age range, 8 to 69 years) were studied 10 to 40 days after hospitalization for hypercalcemia.
Measurements: Serum total 25-hydroxyvitamin D (25-OHD) and 1,25-(OH) (2D) levels were measured by radioreceptor assays. The percentage of free 1,25-(OH)2D was measured by centrifugal ultrafiltration isodialysis and was used to calculate actual free 1,25-(OH)2D levels. In the in vitro studies, vitamin D metabolites (25-OHD; 24,25-[OH]2D; 25,26-[OH]2D; and 25-OHD-26,23 lactone) were added to normal serum in concentrations expected to occur with vitamin D toxicity. The percentage of free 1,25-(OH) (2D) was measured by isodialysis.
Results: All patients presented with marked hypercalcemia (mean calcium level, 3.99 ±0.33 mmol/L). Serum 25-OHD levels ranged from 847 to 1652 nmol/L, and total 1,25-(OH)2D levels (mean, 106 ±86 pmol/L) were elevated in only three patients. The percentage of free 1,25-(OH)2D (mean, 1.023% ±0.366%) was elevated in all nine patients in whom it was measured. Actual free 1,25-(OH)2D levels (mean, 856 ±600 fmol/L) were elevated in six of the nine patients. Total 1,25-(OH)2D levels were correlated with 25-OHD levels (r = 0.66; P = 0.03), whereas total and free 1,25-(OH)2D levels were highly correlated (r = 0.957; P < 0.001). In the in vitro studies, the percentage of free 1,25-(OH)2D increased after 25-OHD or 24,25-(OH)2D was added.
Conclusions: Although the patients had normal or near-normal total 1,25-(OH)2D values, most patients had elevated free 1,25-(OH)2D levels. These findings suggest that elevated free 1,25-(OH)2D levels might play a role in the pathogenesis of hypercalcemia in vitamin D toxicity.
Author and Article Information
From the University of the Witwatersand, Johannesburg, South Africa. The University of California, San Francisco, California. The University of Natal, Durban, South Africa.
BRIEF COMMUNICATION
Serum Levels of Free 1,25-Dihydroxyvitamin D in Vitamin D Toxicity
Requests for Reprints: John M. Pettifor MBBCh, Mineral Metabolism Research Unit, Department of Pediatrics, Baragwanath Hospital, P.O. Bertsham 2013, South Africa.
Acknowledgments: The authors thank Dr. I. Jialal, Dr. M.C. Rajput, and Dr. A.R. Seebaran for their assistance and Dr. P.K. Naidoo, medical superintendent of the R.K. Khan Hospital, Chatsworth, South Africa, for permission to publish.
Grant Support: By a grant from the South African Medical Research Council.
This article has been cited by other articles:
|
|
 |
|
  S. Kimball and R. Vieth Self-prescribed high-dose vitamin D3: effects on biochemical parameters in two men Ann Clin Biochem, January 1, 2008; 45(1): 106 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M Kimball, M. R Ursell, P. O'Connor, and R. Vieth Safety of vitamin D3 in adults with multiple sclerosis Am. J. Clinical Nutrition, September 1, 2007; 86(3): 645 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N Hathcock, A. Shao, R. Vieth, and R. Heaney Risk assessment for vitamin D Am. J. Clinical Nutrition, January 1, 2007; 85(1): 6 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Vieth Critique of the Considerations for Establishing the Tolerable Upper Intake Level for Vitamin D: Critical Need for Revision Upwards J. Nutr., April 1, 2006; 136(4): 1117 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Barrueto Jr,, H. H. Wang-Flores, M. A. Howland, R. S. Hoffman, and L. S. Nelson Acute Vitamin D Intoxication in a Child Pediatrics, September 1, 2005; 116(3): e453 - e456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F Holick Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease Am. J. Clinical Nutrition, December 1, 2004; 80(6): 1678S - 1688S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Tryfonidou, M. A. Oosterlaken-Dijksterhuis, J. A. Mol, T. S. G. A. M. van den Ingh, W. E. van den Brom, and H. A. W. Hazewinkel 24-Hydroxylase: potential key regulator in hypervitaminosis D3 in growing dogs Am J Physiol Endocrinol Metab, March 1, 2003; 284(3): E505 - E513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vieth Reply to FAJ Muskiet et al Am. J. Clinical Nutrition, December 1, 2001; 74(6): 863 - 864. [Full Text]
|
|
|
|
|
|
P. A. Price, J. R. Buckley, and M. K. Williamson The Amino Bisphosphonate Ibandronate Prevents Vitamin D Toxicity and Inhibits Vitamin D-Induced Calcification of Arteries, Cartilage, Lungs and Kidneys in Rats J. Nutr., November 1, 2001; 131(11): 2910 - 2915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lips Vitamin D Deficiency and Secondary Hyperparathyroidism in the Elderly: Consequences for Bone Loss and Fractures and Therapeutic Implications Endocr. Rev., August 1, 2001; 22(4): 477 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vieth Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety Am. J. Clinical Nutrition, May 1, 1999; 69(5): 842 - 856. [Abstract] [Full Text] [PDF]
|
|
Article
